FLT4 antibody (Extracellular Domain)

Catalog No. ABIN115161

This anti-FLT4 antibody is a Mouse Monoclonal antibody detecting FLT4 in WB, IHC (p), IHC (fro) and EIA. Suitable for Human. This Primary Antibody has been cited in 1 publication.

Quick Overview for FLT4 antibody (Extracellular Domain) (ABIN115161)

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This FLT4 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA)

Clone: (3C3) 9D9

Product Details anti-FLT4 Antibody

Binding Specificity: Extracellular Domain

Specificity: Detects Human VEGFR-3/FLT-4.

Cross-Reactivity (Details): Species reactivity (tested):Human.

Purification: Affinity Chromatography on Protein G.

Immunogen: Purified recombinant human Vascular Endothelial Growth Factor Receptor 3 (rh VEGFR-3/FLT-4) extracellular domain.

Isotype: IgG1

Application Details

Application Notes: ELISA: 0.5-1.5 μg/mL in direct ELISA, allows detection of 0.25-0.5 ng/well. Immunohistochemistry: 1-10 μg/mL. Western blot 0.5-1 μg/mL, detection limit is approximately 5 ng/lane under reducingconditions.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Reconstitution: Restore with sterile water to a concentration of 0.1-1.0 mg/mL

Buffer: PBS pH 7.4 without preservatives or stabilizers

Preservative: Without preservative

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: The lyophilized IgG is stable at 2-8 °C for one month and for one year from despatch when kept at -20 °C. When reconstituted in sterile water to a concentration of > 0.5 mg/ml the antibody is stable for six weeks at 2-8 °C or at -20 °C for longer. Aliquot to

Expiry Date: 12 months

References for anti-FLT4 antibody (ABIN115161)

Davids, Davids, Charlton, Ng, Chong, Laubscher, Dar, Hodge, Soong, Goh: "Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 27, Issue 26, pp. e97-100, (2009) (PubMed).

Target Details for FLT4

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Alternative Name: VEGFR-3 / Flt-4

Background: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk 1) and VEGFR-3 (FLT-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. These receptors play essential roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The VEGFR-3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR-3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGF R3 (Flt-4). The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stage of development. It is important for lymphangiogenesis.Synonyms: FLT4, Tyrosine-protein kinase receptor FLT4, VEGF Receptor 3, VEGFR3, Vascular endothelial growth factor receptor 3

Gene ID: 2324

NCBI Accession: NP_002011

UniProt: P35916

Pathways: RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling